Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for Glucose Tolerance
Author(s) -
Róbert Wágner,
Liisa Hakaste,
Emma Ahlqvist,
Martin Heni,
Jürgen Machann,
Fritz Schick,
Emmanuel Van Obberghen,
Norbert Stefan,
Baptist Gallwitz,
Jaakko Tuomilehto,
Hans-Ulrich Häring,
Leif Groop,
Andreas Fritsche
Publication year - 2016
Publication title -
diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.219
H-Index - 330
eISSN - 1939-327X
pISSN - 0012-1797
DOI - 10.2337/db16-0354
Subject(s) - glucagon , medicine , endocrinology , impaired glucose tolerance , insulin , diabetes mellitus , type 2 diabetes , insulin resistance
Glucagon levels are classically suppressed after glucose challenge. It is still not clear as to whether a lack of suppression contributes to hyperglycemia and thus to the development of diabetes. We investigated the association of postchallenge change in glucagon during oral glucose tolerance tests (OGTTs), hypothesizing that higher postchallenge glucagon levels are observed in subjects with impaired glucose tolerance (IGT). Glucagon levels were measured during OGTT in a total of 4,194 individuals without diabetes in three large European cohorts. Longitudinal changes in glucagon suppression were investigated in 50 participants undergoing a lifestyle intervention. Only 66-79% of participants showed suppression of glucagon at 120 min (fold change glucagon 120/0 <1) during OGTT, whereas 21-34% presented with increasing glucagon levels (fold change glucagon 120/0 ≥1). Participants with nonsuppressed glucagon 120 had a lower risk of IGT in all cohorts (odds ratio 0.44-0.53, P < 0.01). They were also leaner and more insulin sensitive and had lower liver fat contents. In the longitudinal study, an increase of fold change glucagon 120/0 was associated with an improvement in insulin sensitivity ( P = 0.003). We characterize nonsuppressed glucagon 120 during the OGTT. Lower glucagon suppression after oral glucose administration is associated with a metabolically healthier phenotype, suggesting that it is not an adverse phenomenon.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom